524816 Stock Overview
A pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
NATCO Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹883.70 |
| 52 Week High | ₹1,638.35 |
| 52 Week Low | ₹868.25 |
| Beta | 0.55 |
| 1 Month Change | -28.70% |
| 3 Month Change | -34.81% |
| 1 Year Change | -13.95% |
| 3 Year Change | 1.81% |
| 5 Year Change | 32.95% |
| Change since IPO | 31,460.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524816 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -33.0% | -7.5% | -5.6% |
| 1Y | -14.0% | 9.0% | -0.9% |
Return vs Industry: 524816 underperformed the Indian Pharmaceuticals industry which returned 9% over the past year.
Return vs Market: 524816 underperformed the Indian Market which returned -0.9% over the past year.
Price Volatility
| 524816 volatility | |
|---|---|
| 524816 Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: 524816's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 524816's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 4,016 | Rajeev Nannapaneni | www.natcopharma.co.in |
NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services.
NATCO Pharma Limited Fundamentals Summary
| 524816 fundamental statistics | |
|---|---|
| Market cap | ₹158.19b |
| Earnings (TTM) | ₹18.65b |
| Revenue (TTM) | ₹42.80b |
8.5x
P/E Ratio3.7x
P/S RatioIs 524816 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524816 income statement (TTM) | |
|---|---|
| Revenue | ₹42.80b |
| Cost of Revenue | ₹6.15b |
| Gross Profit | ₹36.65b |
| Other Expenses | ₹18.00b |
| Earnings | ₹18.65b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 104.13 |
| Gross Margin | 85.62% |
| Net Profit Margin | 43.58% |
| Debt/Equity Ratio | 2.9% |
How did 524816 perform over the long term?
See historical performance and comparisonDividends
0.7%
Current Dividend Yield6%
Payout RatioDoes 524816 pay a reliable dividends?
See 524816 dividend history and benchmarks| NATCO Pharma dividend dates | |
|---|---|
| Ex Dividend Date | Feb 18 2025 |
| Dividend Pay Date | Mar 14 2025 |
| Days until Ex dividend | 2 days |
| Days until Dividend pay date | 26 days |
Does 524816 pay a reliable dividends?
See 524816 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 05:46 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NATCO Pharma Limited is covered by 29 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| Prashant Nair | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |